Zobrazeno 1 - 10
of 183
pro vyhledávání: ''
Publikováno v:
Breast Disease. 40:S1-S7
BACKGROUND: The plasminogen urokinase activation system consists of urokinase plasminogen activator (uPA), its receptor uPAR, and plasminogen activator inhibitor type 1 (PAI-1), which are considered to have a relationship with cancer aggressiveness.
Autor:
Kadir Eser, Pinar Saip, Erdem Cubukcu, Fuat Demirelli, Ozkan Alan, Zuleyha Calikusu, Aykut Bahceci, Ali Alkan, Hacer Demir, Mahmut Büyükşimşek, Cemile Karadeniz, Erhan Gokmen, Naziye Ak, Mehmet Bilici, Altay Aliyev, Turkkan Evrensel, Oznur Bal, Atakan Demir, Özge Keskin, Nilgün Yildirim, Saadettin Kilickap, Semra Paydas, Atike Gökçen Demiray, Kezban Nur Pilanci, Ali Gökyer, Perran Fulden Yumuk, Birol Yildiz, Duygu Ilke Cikman, Ismail Beypinar, Taner Korkmaz, Sinan Yavuz, Burcu Çakar, Erkan Arpaci, Gulsah Seydaoglu, Ferhat Ferhatoglu, Ahmet Z. Sahin, Gulcan Bulut, Serkan Degirmencioglu, Cengiz Karacin, Mutlu Dogan, Havva Yesil Cinkir, Kerem Okutur, Semiha Urvay, Deniz Işik, Melih Simsek, Osman Kostek, Meltem Baykara, Salim Basol Tekin, Deniz Yamac
Publikováno v:
Cancer Investigation. 39:473-481
Aim: The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment. Method: Retrospective analysis of T-DM1 results of human epidermal grow
Autor:
Junyi Ye, Shanai Song, Haiwei Du, Zhou Zhang, Haiyan Li, Ning Liu, Zimin Liu, Xiaoxiao Li, Lu Zhang, Mingpeng Shi
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose The identification of HER2 overexpression in a subset of gastric adenocarcinoma (GA) patients represents a significant step forward in unveiling the molecular complexity of this disease. The predictive and prognostic value of HER2 amplificati
Publikováno v:
Anti-Cancer Drugs. 31:973-978
Tumor human epidermal growth factor receptor 2 (HER2) status is defined by either protein expression using immunohistochemistry (IHC) or gene amplification using fluorescence in situ hybridization (FISH). Approximately 20% of HER2-positive breast can
Autor:
Aidan C Li, Jing Zhao, Ramon Hartage, Yunxiang Zhang, Chao Zhao, Xiaoxian Li, Anil V. Parwani, Zhongliang Ma
Publikováno v:
Breast Cancer Res Treat
PURPOSE: Patients with HER2-positive breast cancer commonly receive anti-HER2 neoadjuvant chemotherapy and pathologic complete response (pCR) can be achieved in up to half of the patients. HER2 protein expression detected by immunohistochemistry (IHC
Autor:
Vanessa Davies, Ioannis A. Voutsadakis
Publikováno v:
Cancer Investigation. 38:94-101
Background: Amplification of the centromeric region of chromosome 17 (CEP17) as measured by In Situ Hybridization (ISH) of the CEP17 probe is used clinically as part of the ISH assay for HER2 statu...
Autor:
Pei Hui, Elena Ratner, Peter E. Schwartz, Masoud Azodi, Natalia Buza, Stefania Bellone, Paola Manara, Burak Zeybek, Mitchell Clark, Aranzazu Manzano, Gary Altwerger, Silvia Pelligra, Elena Bonazzoli, Gulden Menderes, Luca Zammataro, Dennis Mauricio, Gloria S. Huang, Barbara Gnutti, Justin Harold, Vaagn Andikyan, Nupur Nagarkatti, Alessandro D. Santin, Adele Guglielmi, Dan-Arin Silasi, Joan Tymon-Rosario
Publikováno v:
Gynecol Oncol
OBJECTIVE: Uterine serous carcinoma (USC) is an aggressive histologic variant of endometrial cancer which portends a poor prognosis. DHES0815A is a novel antibody-drug-conjugate (ADC) which binds specifically to HER2 overexpressing tumors at a distin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50cc223ce756b3383cec909a8f83f8c1
https://europepmc.org/articles/PMC8722447/
https://europepmc.org/articles/PMC8722447/
Publikováno v:
Pathology, research and practice. 227
Background HER2 was a recognized oncogene that promoted the development and metastasis of breast cancer, but its positive expression rate in invasive ductal carcinoma (IDC) was much lower than that in ductal carcinoma in situ (DCIS). The correlation
Autor:
Michael F. Press, Dennis J. Slamon, Joan S. Brugge, Sara A. Hurvitz, Jason J. Zoeller, Judy Dering, Laura M. Selfors
Publikováno v:
PLoS ONE
PloS one, vol 16, iss 5
PLoS ONE, Vol 16, Iss 5, p e0251163 (2021)
PloS one, vol 16, iss 5
PLoS ONE, Vol 16, Iss 5, p e0251163 (2021)
Our previous pre-clinical work defined BCL-2 induction as a critical component of the adaptive response to lapatinib-mediated inhibition of HER2. To determine whether a similar BCL-2 upregulation occurs in lapatinib-treated patients, we evaluated gen
Publikováno v:
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology
Cellular Oncology, Vol 32, Iss 1-2, Pp 57-65 (2010)
Cellular Oncology, Vol 32, Iss 1-2, Pp 57-65 (2010)
Background: Patients with gastric cancer (GC) have a poor survival and biologicals such as Trastuzumab have not been used routinely in these patients. Existing data on HER2 expression and its clinical relevance in GC are still limited and controversi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1c3dd546244ad55cb07c72b3e643d86
https://ora.ox.ac.uk/objects/uuid:7bfe1b69-4071-48f2-8d28-7dea51965e5e
https://ora.ox.ac.uk/objects/uuid:7bfe1b69-4071-48f2-8d28-7dea51965e5e